A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.

Bill 118 s 3220, also known as the "Tropical Disease Product Priority Review Voucher Program Expansion Act," aims to expand the existing priority review voucher program to include coccidioidomycosis, a fungal infection commonly found in the southwestern United States.

The priority review voucher program was originally established to incentivize pharmaceutical companies to develop treatments for neglected tropical diseases by offering them a voucher that can be used to expedite the review process for another drug. This bill seeks to include coccidioidomycosis in this program, recognizing the importance of preventing and treating this disease, which can be severe and even fatal in some cases.

By expanding the priority review voucher program to include coccidioidomycosis, this bill aims to encourage pharmaceutical companies to invest in research and development for treatments and prevention methods for this disease. This could lead to the development of new and more effective drugs to combat coccidioidomycosis, ultimately benefiting those who are at risk of contracting this infection. Overall, Bill 118 s 3220 seeks to address the public health concern of coccidioidomycosis by providing incentives for pharmaceutical companies to focus on developing treatments and prevention methods for this disease. This could potentially lead to advancements in medical research and improved outcomes for individuals affected by coccidioidomycosis.